Eppendorf announces it has received Connecticut State approval to conduct Biosafety Level 2 infectious disease related research

Eppendorf is proud to announce it has received Connecticut State approval to conduct Biosafety Level 2 (BL2) infectious disease related research. This greatly expands the capabilities of the Eppendorf Research and Development Laboratory, located at its Enfield facility, and enhances research plans and activities for customers. "We plan to further our research in stem cell bioprocess to include induced pluripotent stem cells (IPSCs)," stated D. Ma Sha, Director, Technical Applications. "We are also actively seeking industry or industry/academia collaborations in the stem cell bioprocess area."

Eppendorf Enfield Laboratory image of human mesenchymal stem cells (hMSCs) (Photo: Business Wire)

The method involved in making the IPSC uses viruses to transfer reprogramming genes into regular cells, thus turning these cells into stem cells. These stem cells can then be used in clinical research for the treatment of disease or injury. There are hundreds of clinical trials using such cells listed at www.clinicaltrials.gov. The clinical trial market potential is large, and successful trials would then require the ability to scale up to industry production levels. The Eppendorf bioreactor portfolio, including the New Brunswick CelliGen BLU, can be used to demonstrate large-scale stem cell culture for industry production requirements.

Click here to learn more
http://newbrunswick.eppendorf.com

New Brunswick Scientific
newbrunswick@eppendorf.com